Anteris treats first US patients in PARADIGM trial

Anteris Technologies Global (ASX:AVR) announced a landmark achievement in cardiovascular medicine with the successful treatment of the first American patients in its global pivotal PARADIGM trial.

The procedures, which utilised the company's proprietary DurAVR transcatheter heart valve, were performed by Dr. Azeem Latib at the Montefiore Medical Centre in New York.

The clinical milestone targets patients suffering from severe calcific aortic stenosis, a debilitating condition that restricts blood flow from the heart.

The PARADIGM trial is uniquely engineered to evaluate clinical outcomes that extend beyond standard safety and hemodynamic metrics, specifically focusing on how flow patterns influence left ventricular recovery.

Dr. Latib, the Principal Investigator, described the early procedural results as "highly encouraging," noting that the initiation of US enrolment is a critical step in generating evidence to transform future patient care.

Following recent CMS approval, the Anteris team collaborated rapidly with physician partners to secure these enrolments within just one week.

Wayne Paterson, Vice Chairman and CEO of Anteris, emphasised that this development marks a major milestone as US study sites become operational, significantly expanding the trial’s recruitment capabilities.

At the time of reporting, Anteris Technologies Global’s share price was $8.77.